Truscreen Group

Truscreen Group Net Margin

The Net Profit Margin of Truscreen Group (TRU.NZ) as of Oct 28, 2026 is -131.04 %. In the previous year, Net Profit Margin was -97.28 % — a change of 34.70% (lower).

Net Margin

-131.04 %

YoY

34.70%

Last updated:

Net Profit Margin of Truscreen Group is 2025 -131.04 % . Net Profit Margin of Truscreen Group was 2024 -97.28 % . It decreases by 34.70% lower compared to the previous year.

For Truscreen Group, the net margin of -131.0% is up versus -308.1% a few years ago.

The Truscreen Group Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-518.44 NZD
Jan 1, 2019
-181.45 NZD
Jan 1, 2020
-403.41 NZD
Jan 1, 2021
-308.14 NZD
Jan 1, 2022
-470.22 NZD
Jan 1, 2023
-144.46 NZD
Jan 1, 2024
-97.28 NZD
Jan 1, 2025
-131.04 NZD
The Truscreen Group Net Margin history
YEARNet MarginYoY
-131.04 %+34.70%
-97.28 %-32.66%
-144.46 %-69.28%
-470.22 %+52.60%
-308.14 %-23.62%
-403.41 %+122.32%
-181.45 %-65.00%
-518.44 %-14.28%
-604.82 %+120.17%
-274.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Truscreen Group Stock analysis

What does Truscreen Group do? TruScreen Group Ltd develops and sells cancer detection devices and systems, focusing on cervical cancer screening. The company's AI-enabled device uses opto-electrical technology to detect precancerous and cancerous cervical changes in real-time through optical and electrical measurements of cervical tissue. The TruScreen device includes a Disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC), working together to resolve issues with cytology such as failed samples, poor patient follow-up, and patient discomfort. The company also addresses challenges with HPV testing by providing an alternative solution that avoids the need for laboratory infrastructure. The primary buyers of TruScreen's products are healthcare providers and clinics specializing in women's health, particularly those seeking efficient, real-time cervical screening solutions. The technology targets segments where traditional cytology and HPV testing face limitations, such as in resource-constrained settings or where patient adherence to follow-up is low. By offering a device that eliminates the need for supporting laboratory infrastructure, TruScreen appeals to providers looking to streamline cervical cancer screening processes. TruScreen's products are designed to replace or complement existing cervical screening methods, directly addressing the shortcomings of cytology and HPV testing. The company's focus on real-time detection and ease of use positions it as a solution for healthcare systems aiming to improve early cancer detection rates while reducing patient discomfort and logistical challenges associated with current screening practices. Truscreen Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Truscreen Group stock

Net Profit Margin of Truscreen Group is -131.04 % in 2025.

Net Profit Margin of Truscreen Group changed from -97.28 % to -131.04 %, representing a 34.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Truscreen Group since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Truscreen Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Truscreen Group

All Key Metrics — Truscreen Group